<unk>  is a kinase inhibitor that is FDA approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.   Common adverse reactions include diarrhea, rash, paronychia, stomatitis, decreased appetite, dry skin, decreased weight, alopecia, cough, and pruritus.
Dacomitinib
Baricitinib
Erdafitinib
Axitinib
Ceritinib
Gilteritinib
Fostamatinib
Acalabrutinib